Microvascular angina is chest pain caused by problems in the tiny blood vessels of the heart, rather than blockages in the large coronary arteries. When you picture heart disease, you probably imagine a clogged artery. But in microvascular angina, the major arteries look completely clear on an angiogram. The problem lies deeper, in the small resistance vessels that regulate blood flow to the heart muscle itself. These vessels either fail to widen when the heart needs more oxygen or actively constrict, starving patches of heart tissue and producing real ischemia.
How It Differs From Typical Angina
In classic coronary artery disease, a fatty plaque narrows a large artery by more than 50%, restricting blood flow. Standard tests are designed to find exactly this kind of blockage. Microvascular angina flips the script: the large arteries are open, but the network of tiny downstream vessels doesn’t function properly. This is why the condition was historically dismissed. Patients with clear angiograms were sometimes told nothing was wrong, even though their symptoms and stress test results pointed to genuine oxygen deprivation in the heart.
The chest pain itself also behaves differently. In obstructive coronary disease, angina typically fades within a few minutes of resting or taking a fast-acting nitrate tablet. In microvascular angina, pain after exertion tends to linger for more than 10 to 15 minutes and responds more slowly, or not at all, to nitrates. That poor nitrate response is one of the clinical clues that the problem is microvascular rather than a large-vessel blockage.
What Goes Wrong in the Small Vessels
The inner lining of blood vessels, called the endothelium, acts as a control system. It releases signaling molecules, especially nitric oxide, that tell the surrounding muscle layer to relax and widen the vessel. In microvascular angina, this signaling breaks down. The endothelium becomes dysfunctional, so the small coronary vessels can’t dilate properly when the heart demands more blood during exercise or stress. In some cases, the vessels actually constrict instead of opening up.
The smooth muscle cells wrapped around these tiny arteries can also be part of the problem. In healthy people, certain chemical signals cause these muscles to relax, increasing blood flow. In people with microvascular dysfunction, the relaxation response is blunted. This has been documented in patients with diabetes, high cholesterol, high blood pressure, obesity, smoking history, and kidney disease, all of which damage the microvascular system over time.
Coronary spasm also plays a role. About half of patients with stable chest pain and no obstructive disease show spasm in the small arteries when tested with acetylcholine, a drug used during diagnostic catheterization. This spasm is closely linked to atherosclerosis and endothelial dysfunction, meaning the same risk factors that cause traditional heart disease also fuel microvascular problems.
Why Women Are Disproportionately Affected
Up to 50% of women who undergo coronary angiography for suspected heart disease are found to have no significant blockages, compared to only 17% of men. That means roughly half of the 450,000 women catheterized each year in the United States leave the lab without a traditional explanation for their symptoms. Many of these women have microvascular angina.
The diagnostic gap runs deeper than biology. Standard treadmill stress tests have a sensitivity of only 60 to 70% in women, compared to about 80% in men. Women with heart problems are also more likely to present with nausea, jaw pain, neck pain, or back pain rather than the textbook “crushing chest pressure,” leading clinicians to label their symptoms as atypical. In one large study of over 20,000 patients admitted with acute coronary syndromes, 8.4% had no chest pain at all, and these patients were disproportionately female, older, or had conditions like diabetes. Perhaps most telling: physicians perceive women as being at lower risk for cardiovascular disease even when their calculated risk matches that of men. And 38% of women say their doctors never initiated a conversation about heart disease risk in the first place.
How Microvascular Angina Is Diagnosed
The Coronary Vasomotion Disorders International Study Group (COVADIS) established four criteria that must all be met for a definitive diagnosis: symptoms suggestive of ischemia, objective evidence of reduced blood flow on testing, no significant blockage in the large coronary arteries (less than 50% narrowing), and confirmed microvascular dysfunction through specialized measurement.
If only some criteria are met, the diagnosis is classified as “suspected” rather than definitive. This tiered approach helps doctors avoid both overdiagnosis and the historical problem of dismissing real symptoms.
Non-Invasive Testing
Cardiac PET scanning is the most validated imaging method for detecting microvascular problems without a catheter. It measures blood flow through the heart muscle at rest and during chemically induced stress, then calculates a ratio called myocardial flow reserve (MFR). A ratio below 1.5 suggests the tiny vessels aren’t opening adequately. Cardiac MRI can provide similar information using gadolinium contrast, capturing how quickly and evenly blood perfuses the heart. Well-supplied areas light up brightly, while poorly perfused regions appear darker. MRI has the advantage of no radiation exposure and high spatial resolution.
Invasive Testing
When non-invasive results are inconclusive, doctors can measure microvascular function directly during cardiac catheterization using specialized guidewires. Two key measurements are coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR). CFR assesses how well the entire coronary system can ramp up blood flow under stress. A CFR below 2.0 (measured by thermodilution) or below 2.5 (measured by Doppler) suggests dysfunction. IMR isolates the resistance in the small vessels specifically. A value above 25 indicates abnormally high microvascular resistance. IMR is considered more reproducible than CFR because it’s less affected by fluctuations in heart rate and blood pressure.
Doctors may also inject acetylcholine during catheterization to test whether the small vessels spasm. If the patient’s symptoms and ECG changes reproduce during this provocation without spasm in the large arteries, microvascular spasm is confirmed.
Treatment Options
Because microvascular angina involves different mechanisms than large-vessel disease, the standard toolkit for coronary artery disease doesn’t always translate. European Society of Cardiology guidelines recommend starting with cardiovascular risk factor control: statins, blood pressure management, and lifestyle changes. Aggressive management of diabetes, cholesterol, and blood pressure addresses the root endothelial damage driving the condition.
Beta-blockers are the most commonly used first-line medication for symptom relief. Studies using atenolol (up to 100 mg daily) and nebivolol (up to 5 mg daily) have shown improvements in both symptoms and exercise tolerance. These drugs work by slowing the heart rate and reducing the heart’s oxygen demand, which helps compensate for the limited ability of microvessels to increase flow.
Calcium channel blockers are the next step, particularly for patients who don’t respond to beta-blockers or who have a vasospastic component with symptoms occurring at rest. Verapamil and nifedipine have both improved exercise capacity and reduced symptoms in controlled trials compared to placebo. Diltiazem, at doses around 90 mg daily, has also shown benefit, especially when combined with a statin. These drugs directly relax vascular smooth muscle, counteracting the inappropriate constriction in the microcirculation.
For patients who remain symptomatic despite first-line therapy, ranolazine and ivabradine offer additional options. Both have shown mild to moderate symptom improvement in microvascular angina. Ranolazine works through a different anti-ischemic mechanism than standard drugs, targeting abnormal sodium and calcium handling in heart cells, which may explain why it appears slightly more effective in this population. Ivabradine primarily slows the heart rate through a mechanism similar to beta-blockers, so it adds less when beta-blockers are already on board. Head-to-head comparisons between the two have not shown a clear winner, with one study finding no significant difference in angina frequency after two months of treatment.
Long-Term Outlook
Microvascular angina was once considered benign because the large arteries appeared normal. That view has changed. Patients with confirmed coronary microvascular dysfunction face a higher rate of cardiovascular events than previously recognized, including heart attack, heart failure, and hospitalization. The condition also takes a significant toll on quality of life, with recurring chest pain, limited exercise capacity, frequent emergency visits, and the psychological burden of having symptoms that were historically difficult to explain or validate.
Proper diagnosis matters because it opens the door to targeted treatment and, just as importantly, gives patients a name for what they’re experiencing. The growing recognition of microvascular angina as a distinct and treatable condition has shifted cardiology away from the assumption that clear coronary arteries mean a healthy heart.